1
|
Serbanica AN, Popa DC, Caruntu C, Pasca S, Scheau C, Serbanica IV, Suciu R, Tica V, Busescu E, Cima LN, Jardan C, Dragomir M, Coriu D, Colita A, Colita A. The Significance of CD20 Intensity Variance in Pediatric Patients with B-Cell Precursor Acute Lymphoblastic Leukemia. J Clin Med 2023; 12:jcm12041451. [PMID: 36835986 PMCID: PMC9961970 DOI: 10.3390/jcm12041451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Revised: 02/08/2023] [Accepted: 02/09/2023] [Indexed: 02/16/2023] Open
Abstract
B-cell precursor acute lyphoblastic leukemia (ALL) is a common pediatric malignancy and patients may have significant benefits from monoclonal antibodies therapy with increased survival rates. Positive CD20 expression is identified in about half of these patients and its presence may serve as a prognostic factor in disease evolution. We performed a retrospective study including 114 patients diagnosed with B-ALL and evaluated the expression of CD20 through flow cytometry at diagnosis and on day 15. Additional immunophenotypic analyses as well as cytogenetic and molecular genetic analyses were also performed. We observed an increase in the mean fluorescence intensity (MFI) of CD20 between diagnosis-1.9 (1.2-3.26) and day 15: 6.17 (2.14-27.4), (p < 0.0001). Furthermore, we assessed that both diagnosis and day 15 CD20 MFI had an impact on RFS and OS, respectively, for cut-off values of >8.08 at diagnosis and >28.65 at day 15. In conclusion, CD20 expression appears to be a poor prognostic feature of B-ALL in pediatric patients. In this study, stratification of the outcome by the intensity of CD20 has implications concerning the allocation to rituximab-based chemotherapy and may offer new, potentially useful information for pediatric patients with B-ALL.
Collapse
Affiliation(s)
- Andreea Nicoleta Serbanica
- Department of Pediatrics, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Department of Pediatric Hematology and Stem Cell Transplantation, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Delia Codruta Popa
- Department of Biochemistry, The “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Department of Hematology, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Constantin Caruntu
- Department of Physiology, The “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Department of Dermatology, ‘Prof. N.C. Paulescu’ National Institute of Diabetes, Nutrition and Metabolic Diseases, 011233 Bucharest, Romania
| | - Sergiu Pasca
- Department of Hematology, Iuliu Haţieganu University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania
- Correspondence: (S.P.); (C.S.)
| | - Cristian Scheau
- Department of Physiology, The “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Correspondence: (S.P.); (C.S.)
| | - Ionut Vlad Serbanica
- Department of Pediatrics, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
| | - Raluca Suciu
- Department of Hematology, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Valeria Tica
- Department of Hematology, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Elisa Busescu
- Department of Pediatric Hematology and Stem Cell Transplantation, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Luminita Nicoleta Cima
- Department of Endocrinology and Diabetes, Nutrition and Metabolic Diseases—“Elias” Emergency University Hospital, 011461 Bucharest, Romania
- Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
| | - Cerasela Jardan
- Department of Pediatrics, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Department of Hematology, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Mihaela Dragomir
- Department of Hematology, Fundeni Clinical Institute, 022328 Bucharest, Romania
| | - Daniel Coriu
- Department of Hematology, Fundeni Clinical Institute, 022328 Bucharest, Romania
- Department of Hematology, Carol Davila University of Medicine and Pharmacy, 420003 Bucharest, Romania
| | - Andrei Colita
- Department of Hematology, Carol Davila University of Medicine and Pharmacy, 420003 Bucharest, Romania
- Department of Hematology, Coltea Hospital, 420003 Bucharest, Romania
| | - Anca Colita
- Department of Pediatrics, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Department of Pediatric Hematology and Stem Cell Transplantation, Fundeni Clinical Institute, 022328 Bucharest, Romania
| |
Collapse
|
2
|
Popescu GC, Rababoc R, Mercan-Stanciu A, Dodot M, Isac T, Toma L, Zgura A, Trifan A, Serbanica AN, Micu L, Iliescu L. EVOLUTION OF FIBROSIS, INFLAMMATION, STEATOSIS AND STEATOHEPATITIS IN HCV INFECTED PATIENTS AFTER TREATMENT WITH DIRECT- ACTING ANTIVIRAL THERAPY (A FIBROMAX® ANALYSIS). ArveMED 2022. [DOI: 10.35630/2022/12/6.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Aim: The aim of this study is to assess the evolution of Fibromax® parameters (fibrosis, inflammation, steatosis, steatohepatitis) in patients with chronic HCV hepatitis at one year after sustained virologic response (SVR) achieved by direct acting antiviral agents (DAA). Methods: This is a retrospective observational trial including 73 patients with chronic HCV hepatitis, who obtained sustained virologic response under ombitasvir/paritaprevir/ritonavir and dasabuvir, ledipasvir/sofosbuvir or sofosbuvir/velpatasvir. All the patients were evaluated by Fibromax before the initiation of therapy and at 12 months after SVR. Results and Conclusion: The study included 42 women (57.53%) and 31 men (42.46%), without significant difference in mean age or BMI. We found a higher prevalence of patients with minimal or moderate fibrosis (F1, F2), compared to patients with advanced fibrosis (F3) (63.01% versus 10.95%). At one year follow-up, we found an increased number of patients in the lower levels of fibrosis, inflammation and NASH, with a relatively constant distribution of patients regarding steatosis. Necro-inflammatory activity was significantly diminished, with 58 patients in the no to minimal activity, compared to 37 patients before antiviral therapy. More patients presented N0 and N1 degree of NASH at follow-up than before therapy (63 patients versus 42 patients, p= 0.02). The mean values of Fibrotest (p= 0.03), ActiTest (p<0.01) and NashTest (p=0.02) decreased significantly. The mean value of Steatotest also decreased, but without statistical significance (p=0.12).
Collapse
|
3
|
Gică N, Peltecu G, Chirculescu R, Gică C, Stoicea MC, Serbanica AN, Panaitescu AM. Ovarian Germ Cell Tumors: Pictorial Essay. Diagnostics (Basel) 2022; 12:diagnostics12092050. [PMID: 36140449 PMCID: PMC9498179 DOI: 10.3390/diagnostics12092050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2022] [Revised: 08/11/2022] [Accepted: 08/19/2022] [Indexed: 11/16/2022] Open
Abstract
Ovarian germ cell tumors of the ovary represent a histologically heterogenous group of tumors with a high incidence at reproductive age. Patients with this pathology are very often young women with amenorrhea. The aim of this article is to present a pictorial essay of this rare pathology and to promote a national tumor registry and protocol. The treatment is individualized according to age, and fertility-sparing surgery is the actual standard of surgical treatment for young patients in early stage of the disease.
Collapse
Affiliation(s)
- Nicolae Gică
- Department of Obstetrics and Gynecology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
- Filantropia Clinical Hospital, 011132 Bucharest, Romania
| | - Gheorghe Peltecu
- Department of Obstetrics and Gynecology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
- Filantropia Clinical Hospital, 011132 Bucharest, Romania
- Correspondence:
| | - Raluca Chirculescu
- Department of Obstetrics and Gynecology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
- Filantropia Clinical Hospital, 011132 Bucharest, Romania
| | - Corina Gică
- Department of Obstetrics and Gynecology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
- Filantropia Clinical Hospital, 011132 Bucharest, Romania
| | | | - Andreea Nicoleta Serbanica
- Department of Pediatrics, Fundeni Clinical Institute, Department of Pediatrics Hematology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
| | - Anca Maria Panaitescu
- Department of Obstetrics and Gynecology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
- Filantropia Clinical Hospital, 011132 Bucharest, Romania
| |
Collapse
|